Staff Reports
Sevindik Huseynov, an Azerbaijani national and the CEO of a sham durable medical equipment company called Vonyes Inc., pleaded guilty in federal court to three counts of health care fraud after prosecutors say he tried to siphon roughly $137 million from Medicare Advantage plans with fake billing and fake patients.
The scheme and the shocking numbers
Federal prosecutors say Vonyes submitted more than 7,200 claims to at least eight Medicare Advantage Organizations, billing roughly $137 million for orthotic braces, wound dressings, and other high‑value DME items that patients never ordered or received. Investigators flagged a jaw‑dropping spike in billings—about $89 million in a single month—behavior they call a classic “bust‑out” fraud. Huseynov admitted he deposited roughly $2.8 million in reimbursement checks and wired most of the money overseas to bank accounts in Hong Kong.
How the fraud worked
Barely a company, plenty of red flags
According to court documents, the scam relied on quickly created corporate shells, bogus National Provider Identifiers, and stolen or fabricated beneficiary and doctor information. Identical claim lines, clustering of expensive items, and out‑of‑state referring providers were all red flags investigators point to. In plain English: a flimsy shell of a company filed thousands of phony claims and hoped no one would notice until the money was gone.
Why this guilty plea matters
This is not just another white‑collar headline. The Huseynov plea is part of a broader, nationwide crackdown on Medicare Advantage and DME fraud led by the Department of Justice’s new National Fraud Enforcement Division. The case shows how weak controls and slow reactions cost taxpayers big money and hurt the integrity of programs meant for seniors. Sentencing is set before U.S. District Judge Noël Wise, and while the statutory maximums look strict on paper, the court will weigh guidelines and realities when imposing a sentence on February 2, 2027.
Fixes we should demand
Good work by prosecutors deserves applause, but applause doesn’t stop fraud. We need faster supplier vetting, stronger beneficiary identity checks, and real penalties that make wired‑away millions harder to recover. CMS should expand supplier barring and MA plans must own more of the oversight burden. And a final thought for would‑be scammers: when a company exists for just a few months and bills nine figures, maybe don’t be surprised when Uncle Sam knocks.
